Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 52

1.

Decitabine rescues Cisplatin resistance in head and neck squamous cell carcinoma.

Viet CT, Dang D, Achdjian S, Ye Y, Katz SG, Schmidt BL.

PLoS One. 2014 Nov 12;9(11):e112880. doi: 10.1371/journal.pone.0112880. eCollection 2014.

PMID:
25391133
[PubMed - in process]
Free PMC Article
2.

Advances in treating acute myeloid leukemia.

Showel MM, Levis M.

F1000Prime Rep. 2014 Oct 1;6:96. doi: 10.12703/P6-96. eCollection 2014. Review.

PMID:
25374674
[PubMed]
Free PMC Article
3.

Epigenetic therapy of acute myeloid leukemia using 5-aza-2'-deoxycytidine (decitabine) in combination with inhibitors of histone methylation and deacetylation.

Momparler RL, Côté S, Momparler LF, Idaghdour Y.

Clin Epigenetics. 2014 Oct 1;6(1):19. doi: 10.1186/1868-7083-6-19. eCollection 2014.

PMID:
25313314
[PubMed]
Free PMC Article
4.

Low-dose decitabine-based chemoimmunotherapy for patients with refractory advanced solid tumors: a phase I/II report.

Fan H, Lu X, Wang X, Liu Y, Guo B, Zhang Y, Zhang W, Nie J, Feng K, Chen M, Zhang Y, Wang Y, Shi F, Fu X, Zhu H, Han W.

J Immunol Res. 2014;2014:371087. doi: 10.1155/2014/371087. Epub 2014 May 21.

PMID:
24963497
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Profile of sapacitabine: potential for the treatment of newly diagnosed acute myeloid leukemia in elderly patients.

Lim MY, Jamieson K.

Clin Interv Aging. 2014 May 6;9:753-62. doi: 10.2147/CIA.S39558. eCollection 2014. Review.

PMID:
24851045
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies.

Im AP, Sehgal AR, Carroll MP, Smith BD, Tefferi A, Johnson DE, Boyiadzis M.

Leukemia. 2014 Sep;28(9):1774-83. doi: 10.1038/leu.2014.124. Epub 2014 Apr 4. Review.

PMID:
24699305
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Survival and hospitalization among patients with acute myeloid leukemia treated with azacitidine or decitabine in a large managed care population: a real-world, retrospective, claims-based, comparative analysis.

Smith BD, Beach CL, Mahmoud D, Weber L, Henk HJ.

Exp Hematol Oncol. 2014 Mar 25;3(1):10. doi: 10.1186/2162-3619-3-10. Erratum in: Exp Hematol Oncol. 2014;3:19.

PMID:
24666795
[PubMed]
Free PMC Article
8.

Relationship between baseline white blood cell count and renal and hepatic function in older patients with acute myeloid leukemia.

Delaunay J, Mazur G, Minden M, Wierzbowska A, Jones MM, Berrak E, Kantarjian HM.

Leuk Res Rep. 2013 Dec 27;3(1):17-20. doi: 10.1016/j.lrr.2013.12.001. eCollection 2014.

PMID:
24596676
[PubMed]
Free PMC Article
9.

Decitabine in the treatment of acute myeloid leukemia in elderly patients.

Malik P, Cashen AF.

Cancer Manag Res. 2014 Feb 3;6:53-61. doi: 10.2147/CMAR.S40600. eCollection 2014. Review.

PMID:
24520204
[PubMed]
Free PMC Article
10.

Multivariate and subgroup analyses of a randomized, multinational, phase 3 trial of decitabine vs treatment choice of supportive care or cytarabine in older patients with newly diagnosed acute myeloid leukemia and poor- or intermediate-risk cytogenetics.

Mayer J, Arthur C, Delaunay J, Mazur G, Thomas XG, Wierzbowska A, Ravandi F, Berrak E, Jones M, Li Y, Kantarjian HM.

BMC Cancer. 2014 Feb 6;14:69. doi: 10.1186/1471-2407-14-69.

PMID:
24498872
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Sequential treatment with cytarabine and decitabine has an increased anti-leukemia effect compared to cytarabine alone in xenograft models of childhood acute myeloid leukemia.

Leonard SM, Perry T, Woodman CB, Kearns P.

PLoS One. 2014 Jan 28;9(1):e87475. doi: 10.1371/journal.pone.0087475. eCollection 2014.

PMID:
24489920
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies.

Bogenberger JM, Kornblau SM, Pierceall WE, Lena R, Chow D, Shi CX, Mantei J, Ahmann G, Gonzales IM, Choudhary A, Valdez R, Camoriano J, Fauble V, Tiedemann RE, Qiu YH, Coombes KR, Cardone M, Braggio E, Yin H, Azorsa DO, Mesa RA, Stewart AK, Tibes R.

Leukemia. 2014 Aug;28(8):1657-65. doi: 10.1038/leu.2014.44. Epub 2014 Jan 23.

PMID:
24451410
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Acute myeloid leukemia: potential for new therapeutic approaches targeting mRNA translation pathways.

Altman JK, Platanias LC.

Int J Hematol Oncol. 2013 Jun;2(3). doi: 10.2217/ijh.13.23.

PMID:
24319589
[PubMed]
Free PMC Article
14.

Update on optimal management of acute myeloid leukemia.

El Rassi F, Arellano M.

Clin Med Insights Oncol. 2013 Aug 12;7:181-97. doi: 10.4137/CMO.S8528. eCollection 2013.

PMID:
23997579
[PubMed]
Free PMC Article
15.

Phase I study of azacitidine and bortezomib in adults with relapsed or refractory acute myeloid leukemia.

Walker AR, Klisovic RB, Garzon R, Schaaf LJ, Humphries K, Devine SM, Byrd JC, Grever MR, Marcucci G, Blum W.

Leuk Lymphoma. 2014 Jun;55(6):1304-8. doi: 10.3109/10428194.2013.833333. Epub 2013 Sep 9.

PMID:
23952243
[PubMed - in process]
Free PMC Article
16.

The combination of valproic acid, all-trans retinoic acid and low-dose cytarabine as disease-stabilizing treatment in acute myeloid leukemia.

Fredly H, Ersvær E, Kittang AO, Tsykunova G, Gjertsen BT, Bruserud O.

Clin Epigenetics. 2013 Aug 1;5(1):13. doi: 10.1186/1868-7083-5-13.

PMID:
23915396
[PubMed]
Free PMC Article
18.

Treatment of acute myeloid leukemia with 20-30% bone marrow blasts.

Maurillo L, Buccisano F, Del Principe MI, Sarlo C, Di Caprio L, Ditto C, Giannotti F, Nasso D, Ceresoli E, Postorino M, Refrigeri M, Amadori S, Venditti A.

Mediterr J Hematol Infect Dis. 2013 Jun 3;5(1):e2013032. doi: 10.4084/MJHID.2013.032. Print 2013.

PMID:
23795270
[PubMed]
Free PMC Article
19.

Loss of imprinting of IGF2 and the epigenetic progenitor model of cancer.

Leick MB, Shoff CJ, Wang EC, Congress JL, Gallicano GI.

Am J Stem Cells. 2011 Aug 19;1(1):59-74. Print 2012.

PMID:
23671798
[PubMed]
Free PMC Article
20.

Low dose decitabine treatment induces CD80 expression in cancer cells and stimulates tumor specific cytotoxic T lymphocyte responses.

Wang LX, Mei ZY, Zhou JH, Yao YS, Li YH, Xu YH, Li JX, Gao XN, Zhou MH, Jiang MM, Gao L, Ding Y, Lu XC, Shi JL, Luo XF, Wang J, Wang LL, Qu C, Bai XF, Yu L.

PLoS One. 2013 May 9;8(5):e62924. doi: 10.1371/journal.pone.0062924. Print 2013.

PMID:
23671644
[PubMed - indexed for MEDLINE]
Free PMC Article
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk